LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

G-iliac™ Pro Iliac Artery Stent Graft System Obtained Official Registration Approval from the China NMPA

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 7 January 2026, the G-iliac™ Pro iliac artery stent graft system ("**G-iliac™ Pro**" or the "**Product**"), a device independently developed by the Company, obtained official registration approval from the China National Medical Products Administration ("**NMPA**"). The Product is indicated for the endovascular treatment of abdominal aortic aneurysms combined with iliac artery aneurysms or isolated common iliac artery aneurysms. It ensures pelvic blood supply through internal iliac artery reconstruction, providing a more mature and improved solution for clinical practice, thereby achieving a systematic upgrade of existing treatment protocols.

The internal iliac artery, a major branch of the common iliac artery, plays a crucial role in the blood supply to pelvic organs, gluteal muscles, and the spinal cord. In early endovascular aneurysm repair ("**EVAR**") procedures, unilateral or bilateral embolization of internal iliac arteries was often performed to prevent endoleaks. This practice, however, led to a series of complications, including buttock claudication, sexual dysfunction, colonic ischemia, rectal necrosis, spinal cord deficits, and even paraplegia, thus severely compromising patients' long-term quality of life. Numerous domestic and international guidelines and consensus statements have clearly established that preserving at least one internal iliac artery during EVAR can

lead to favorable patient outcomes. The Iliac Branch Device ("**IBD**") technique, due to its superior anatomical alignment, lower endoleak rate, and higher long-term patency rate, has gradually emerged as the preferred endovascular approach for internal iliac artery reconstruction.

G-iliac™ iliac artery bifurcation stent graft system (originally named Lifeflow™ iliac artery bifurcation stent graft system, "**G-iliac™**") has been approved for marketing by the NMPA in 2021 and has become the first ready-to-use IBD device in China, thereby filling the longstanding market gap in the field of endovascular reconstruction of the internal iliac artery. Multicenter clinical applications and real-world studies have demonstrated that the G-iliac™ excels in safety, patency rate, and procedural stability, enabling physicians to more efficiently perform internal iliac artery reconstruction in complex anatomical conditions.

The G-iliac™ Pro consists of the G-iliac™ Pro stent graft and the SilverFlow™ Pro stent graft. Building upon the advantages of G-iliac™, such as its two-component modular design ensuring safe and convenient use; long and short main body design enabling widely adaptable operation; approaches supporting both crossover and brachial artery access providing physicians with greater flexibility; and also building upon the advantages of the interwoven structure of SilverFlow™ enabling excellent flexibility with higher long-term patency rate, the G-iliac™ Pro has been comprehensively upgraded to meet clinical needs in the following respects:

- Low-profile delivery system: flexible and navigable, offering a superior solution for patients with narrow access blood vessels;

- Ergonomic delivery system design: friendly operation, precise and capable of controllable release;

- Latest hydrophilic coating technology: smoother and conducive to smooth introduction of devices;

- Braided sheath tube combined with soft sheath core: optimizing push and passage, and undeterred by complex anatomy;

- Clearer mark design: helping with precise intraoperative positioning.

The approval for marketing of the Product represents a significant advancement for the Group's mature technology platform. It not only further enhances the Company's innovative product layout in the field of full endovascular aortic minimally invasive treatment but also provides an optimized solution for internal iliac artery reconstruction. Dedicated to offering the most comprehensive aortic minimally invasive treatment solutions, the Group continues to drive the minimally invasive surgery treatment of complex aortic diseases toward a new stage of development characterized by greater systematization, standardization, precision, and efficiency.

As the commercialization process advances, the Company will continue to collaborate with industry experts to promote the research, development, and market introduction of medical device products for urgent clinical needs, driving the Group's growth in the medical device field and benefiting a wide range of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 8 January 2026

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong, Ms. WU Liping, Mr. FANG Yu and Ms. FENG Xiaoling being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. WANG Wansong, Mr. ZHOU Luming and Ms. CHEN Dongxia being independent non-executive Directors.